Oxford Science Park sells development site to Ellison Institute for Transformative Medicine

US-based research organisation, the Lawrence J. Ellison Institute for Transformative Medicine, is significantly expanding its commitment to Oxford by establishing a major presence at The Oxford Science Park (TOSP), a leading Europe location for science and technology companies.

To facilitate the development of the Ellison Institute’s new Oxford campus, TOSP has agreed to sell a 150-year lease on a 3.5 acre site in the Park. This will connect directly with the adjacent 5.9-acre Littlemore House site that the Ellison Institute acquired in December 2021, creating a major presence in Oxford. The Ellison Institute’s Oxford campus will provide a permanent home to research laboratories, a patient clinic, offices, and collaborative spaces supporting Ellison Institute projects, including the Global Health Security Consortium’s work on pandemic preparedness.

The development will enable the Ellison Institute to collaborate extensively with companies and organisations across the Park, as well as the wider Oxford innovation ecosystem. The new location also enables the Ellison Institute to expand its existing partnership with Oxford Nanopore Technologies, one of the major international companies based at the Park.

Rory Maw, CEO of The Oxford Science Park, said, ‘We’re delighted to welcome the Ellison Institute to the Park and look forward to working with the team to help deliver their vision for the new Oxford campus. This commitment will reinforce the ground-breaking research and development already taking place on the Park, delivering benefits and opportunities for our occupiers and the wider Oxford innovation ecosystem.’

Dinah Rose QC, President of Magdalen College, said: “Following closely on from our strategic partnership with GIC, the Singapore sovereign wealth fund, this is an exciting next step in the evolution of the Park. We look forward to developing a close long-term relationship with the Ellison Institute and to enhancing further Oxford’s enormous contribution to addressing global health challenges."

Dr David Agus, founding director and CEO of the Ellison Institute, said: "We look forward to continuing the development of our Oxford presence and partnerships. These acquisitions give us greater capacity to undertake critical biomedical research as well as the educational initiatives of the Institute in collaboration with Oxford University."

The Lawrence J. Ellison Institute leverages technology, sparks innovation, and drives interdisciplinary, evidence-based research to reimagine and redefine cancer treatment, enhance health, and transform lives. Under the leadership of Dr. David Agus, the Institute’s goal is to redefine medicine by bringing together a diverse set of clinicians, scientists, and thought leaders to collaborate and drive innovation in cancer treatment, infectious disease, and overall human health.